Related Experiment Video
Updated: Apr 25, 2026
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Is the African Vaccine Manufacturing Accelerator a decoupling mechanism?
1Doctoral Student, Ivey Business School, Western University, 1255 Western Road, London, Ontario, Canada N6G 0N1; Affiliate Trainee at the Centre for Research on Health Equity and Social Inclusion c/o Innovation Works 201 King Street, London, Ontario, Canada N6A 1C9.
Abstract:
This article explores how the African Vaccine Manufacturing Accelerator can support the sustainable production of vaccines in Africa. It highlights the value of the accelerator in relation to the Regional Vaccine Manufacturing Collaborative. The author proposes that this novel financing instrument should be well-designed and implemented in line with the targets of the Partnerships for African Vaccine Manufacturing. It should not be a decoupling tool to appease the institutional environment of the global vaccine market, but a sustainable demonstration of the goodwill and commitment of political and technical leaders to ensure equitable access to routine and epidemic-related vaccines in Africa.
